APA (7th ed.) Citation

Campani, C., Bamba‐Funck, J., Campion, B., Sidali, S., Blaise, L., Ganne‐Carrié, N., . . . Nault, J. (2023). Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab–bevacizumab. Liver International, 43(3), 708. https://doi.org/10.1111/liv.15487

Chicago Style (17th ed.) Citation

Campani, Claudia, et al. "Baseline ALBI Score and Early Variation of Serum AFP Predicts Outcomes in Patients with HCC Treated by Atezolizumab–bevacizumab." Liver International 43, no. 3 (2023): 708. https://doi.org/10.1111/liv.15487.

MLA (9th ed.) Citation

Campani, Claudia, et al. "Baseline ALBI Score and Early Variation of Serum AFP Predicts Outcomes in Patients with HCC Treated by Atezolizumab–bevacizumab." Liver International, vol. 43, no. 3, 2023, p. 708, https://doi.org/10.1111/liv.15487.